Background: We explored the feasibility and the histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma. Results: In all, 41 patients were enrolled; 38 (93%) received ‡47 Gy; 30 patients (73%) received ‡75% of the prescribed doses of chemotherapy. Among 40 assessable patients, 27 (67.5%; 95% confidence interval 50.9% to 81.4%) were successfully treated (entire dose of radiation, ‡75% of the chemotherapy dose, no grade 4 nonhematologic toxicity). In all, 26 patients (63%) underwent surgical resection with curative intent and 21 (80.7%) had R0 resection. A total of 13 of 26 specimens (50%) presented a major pathologic response ( ‡80% of severely degenerative cancer cells), with one complete pathologic response. Operative mortality was 2.8%. The local recurrence and 2-year survival rates were 4% and 32%, respectively, for the 26 operated patients.
introduction
Pancreatic cancer is a leading cause of mortality in developed countries and accounts for 30 000 deaths each year in the United States [1] . Only 10%-15% of patients presenting with pancreatic adenocarcinoma can undergo a potentially curative surgical resection [1] . Even among this favorable subset of patients, results of surgery alone are poor, with a >80% rate of local or distant recurrence and a survival rate not exceeding 20% at 5 years [1, 2] . Recent data suggest that a multimodality approach combining surgery and adjuvant chemotherapy with or without external-beam radiation therapy improves local control and survival duration compared with surgery alone in patients with potentially resectable pancreatic cancer [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . In North America, the controversial results of the ESPAC 1 trial [4] have generally not influenced the standard of care; adjuvant chemoradiotherapy remains a standard approach. However, there is a growing interest in the preoperative chemoradiotherapy approach for several reasons [13, 14] : (i) the possibility to minimize the risk of dissemination during surgical procedure and to increase the R0 resection rate, which is an independent predictor of survival in different surgical series [2, 9, [15] [16] [17] [18] [19] [20] ; (ii) the possibility to deliver the entire planned schedule, if one considers that 25% of patients do not complete planned adjuvant therapy due to surgical complications or prolonged recovery time of performance status [2, 9, 21] ; (iii) the possibility to identify patients who are unlikely to benefit from surgery, as up to 25% of patients will present with rapidly progressive or disseminated disease at restaging [14] ; (iv) the reduction of overall treatment time, important parameter for the quality of life of patients for whom median survival is short; (v) a better radiation responsiveness, the radiation being delivered to nondevascularized and welloxygenated tissues, and (vi) the possibility to spare the surgical anastomosis, most of preoperatively irradiated tissues being resected with the surgical procedure. However, this schedule requires a pretherapeutic confirmation of malignancy, a biliary decompression in case of biliary obstruction and can lead to an overtreatment of patients that could have shown metastatic disease on initial laparotomy, and for whom standard treatment would have been chemotherapy alone. In 1998, the French Society of Radiation Oncology (SFRO) and the Francophone Foundation of Digestive Oncology (FFCD) initiated a multi-institutional prospective phase II trial to evaluate the feasibility of a preoperative 5-fluorouracil (5-FU) and cisplatin-based chemoradiation regimen for treatment of potentially resectable pancreatic cancer. Efficacy of chemoradiation was defined in terms of histopathological response rate, complete resection rate, and locoregional control rate. We analyzed the results of this trial and reviewed the literature with a special highlight on the treatment effect.
patients and methods
eligibility criteria
The Biomedical Research Promotion Consultative Committee of Lyon, France, approved the study protocol and all patients gave written informed consent. Inclusion criteria included the following: (i) newly diagnosed and histologically or cytologically proven American Joint Committee on Cancer Staging clinical stage I, II, or III ductal pancreatic adenocarcinoma [22] ; (ii) age from 18 to 75 years; (iii) Eastern Cooperative Oncology Group performance status (£2) [23] ; (iv) complete history and physical examination, staging evaluation requiring abdominal ultrasound, chest radiography, thoracic and abdominal-pelvic computed tomography (CT) and/or magnetic resonance imaging (MRI); celiomesenteric arteriography and endoscopic ultrasound were optional; laparoscopy was initially optional but became mandatory in January 2001 to avoid any inclusion of patients with peritoneal undetectable occult metastases; (v) no distant detectable metastases; (vi) initial tumor considered as potentially resectable by the surgeon; (vii) no previous antitumoral treatment except placement of a biliary stent; (viii) adequate hematologic, hepatic, renal, and cardiopulmonary functions. Excluded were patients with any other previous or concurrent malignant disease or with any infectious or other medical condition (especially liver failure with a prothrombin time <60% and digestive occlusion requiring surgical bypass) that would have precluded chemotherapy or radiotherapy.
chemoradiation and surgery
As shown in Figure 1 , treatment started with concurrent chemoradiation. Radiotherapy target volumes were established by CT scan and/or MRI. The target volume included the pancreatic tumor and the potentially involved nodes (>1 cm on CT scan), with a 3-cm field margin. All treatments were delivered through three to four fields of 15-20 MV photons. Total dose was 50 Gy in 25 daily 2 Gy-fractions over 5 weeks. Chemotherapy started the same day as radiation therapy and consisted of five cycles of 120-h continuous infusion of 5-FU (300 mg/m 2 /day, 5 days/week, five consecutive weeks) combined with a daily cisplatin i.v. bolus of 20 mg/m 2 (with prior hydration) on days 1-5 and days 29-33. A 5-FU-based chemoradiation regimen was chosen because it has been previously studied either in the adjuvant setting or in locoregional advanced disease [2, 3, 13, 21] . However, to our knowledge, no data were available regarding the feasibility of a preoperative 5-FU-and cisplatin-based chemoradiation regimen for treatment of potentially resectable pancreatic cancer at the beginning of this phase II trial. Chemotherapy dose modifications for hematologic toxic effects were made as follows: full doses of 5-FU and cisplatin were given for absolute neutrophils count (ANC) ‡1500/mm 3 and platelets count ‡75 000/mm 3 ; when ANC was between 1000/mm 3 and 1500/mm 3 , doses were reduced to 50%; if ANC was <1000/mm 3 or platelets count <75 000/ mm 3 , chemotherapy was delayed until normalization and was reinstituted at 50%. Chemotherapy was completely stopped after a second interruption caused by hematologic toxicity. A preoperative work-up was carried out 8 weeks after the beginning of the treatment to assess the resectability of the pancreatic tumor. Surgical resection was carried out 3-6 weeks after completion of concurrent chemoradiation in patients who remained free of disease progression leading to an unresectable status, prohibitive decline in performance status, and distant metastasis. Pancreatectomy had the objective of achieving complete resection of the tumor with extended peripancreatic and celiomesenteric lymph node sampling. Evaluation of the primary outcome was carried out at week 16. feasibility and measurement of treatment effect toxicity and response assessment. Toxicity of the treatment was evaluated using the early toxicity criteria of the World Health Organization (WHO) [24] as well as the scale for late effects by the European Organization for Research and Treatment of Cancer and the Radiation Therapy and Oncology Group [25] . Surgery-related morbidity and mortality events were those occurring within the first 30 postoperative days or during the hospitalization after the procedure. The current WHO standard criteria were used to assess the response to preoperative treatment [26] . Final response evaluation was carried out by one experienced radiologist (P-JV).
feasibility. The primary end point was determination of the proportion of patients having received (16 weeks after inclusion) all the components of the preoperative treatment. Success consisted of a patient being alive, having received the entire dose of radiation and ‡75% of the chemotherapy dose, without extra-hematologic toxicity more than grade 3. Centralized evaluation of the primary end point was carried out by a multidisciplinary independent committee. Secondary end points evaluated the efficacy of the proposed chemoradiation scheme in terms of histopathological response and resectability rates, locoregional control rate, and global efficiency of the therapeutic strategy (defined by the completion of the primary end point and surgical resection and 1-year and 2-year survival).
evaluation of the histopathological response to preoperative chemoradiation. Macroscopical examination, sampling of surgical original article Annals of Oncology specimens, and initial microscopical examination were carried out in each participating center according to current international recommendations. Intraoperative assessment and incking of the margin closest to the SMA was recommended. Representative samples were taken from the center and the periphery of the tumor, the adjacent peritumoral tissue, and the distant residual pancreatic tissue. They were fixed in formalin, embedded in paraffin, and processed according to routine histopathological techniques. All tissue sections were stained by hematoxylin-eosin-saffron. Histopathologic response to preoperative chemoradiation was scored in all resected surgical specimens by a gastrointestinal pathologist using a previously published scoring scheme [27] . The following macroscopic and microscopic data were retrieved from the original histopathological reports: (i) tumor size, corresponding to the largest tumor diameter measured before fixation, (ii) status of the resection margins, (iii) evidence of regional lymph node involvement, and (iv) evidence of vascular or perineural invasion. The design of the study included a centralized review of the available histological documents, in order to standardize the evaluation of the chemoradiosensitivity of pancreatic adenocarcinoma according to validated histopathological criteria, without assessment of further biomarkers. The following criteria were assessed: (i) histological typing and degree of histological differentiation of the tumor, as defined by the current WHO classification, (ii) evidence of histopathological response to chemoradiation, and (iii) consequences of chemoradiation on non tumoral tissue. The histopathological response was evaluated on the following criteria: (i) evidence of complete necrosis, (ii) identification of so-called severely degenerative cancer cells (SDCC), according to previously defined morphological criteria, including nuclear pyknosis or karyorrhexis, cytoplasmic vacuolization, or ballooning: the percentage of SDCC and their distribution (homogeneous or heterogeneous, peripheral, or central within the tumor) were assessed according to previous classifications [27] . The consequences of chemoradiation on nontumoral tissue were assessed through the evaluation of the degree of fibrosis and the severity of vascular lesions in the stroma and the peritumoral tissue. Finally, two additional criteria were assessed: (a) the presence of intra-and peritumoral inflammatory infiltrates, their composition, and distribution and (b) the existence of histological signs of chronic pancreatitis in the residual pancreatic tissue. Tumor response was defined as complete, major, moderate, or minor. Complete response was defined by the absence of residual tumor at histopathological examination. Major response was defined by a proportion of SDCC of >80% of tumor cells, the presence of large areas of complete necrosis and a type A pattern of distribution of nonviable cells according to Ishikawa classification. Moderate response was defined by a proportion of SDCC comprised between 50% and 80% of tumor cells, the presence of small and spotty areas of complete necrosis, and type A or B patterns of distribution of non viable cells according to Ishikawa classification. Minor response was defined by a proportion of SDCC of <50% of tumor cells, the absence of complete necrosis, and a type C pattern of distribution of nonviable cells according to Ishikawa classification. Overall pathologic response was defined by a complete or major response to preoperative chemoradiation.
follow-up and statistical analysis
After surgery, patients were then monitored by physical examination, chest radiography, and abdominal CT scan every 4 months during the first year and every 6 months thereafter. Concerning the primary end point, for a treatment feasibility rate of 75% with a 5% a risk and a 10% b risk, 31 patients were required to reject the null hypothesis of a feasibility rate of 50%. Survival was calculated as the time from inclusion to death or date of final analyses (31 March 2003 Tables 1 and 2 . Characteristics of patients and tumors did not differ between patients who underwent laparoscopy at initial staging (n = 14) and those who did not (n = 27) (data not shown). A total of 38 patients (93%) received ‡47 Gy (94% of the target dose). With regard to chemotherapy, 30 patients (73%) received at least 75% of the prescribed 5-FU and cisplatin doses. Eleven patients (27%) received <75% of the dose for the two drugs; seven of these patients had actually received 74.6% of the theoretical dose for one of the two drugs (Figure 2 ). The main reasons for stopping radiotherapy and/or chemotherapy were infection and hematologic toxic effects (Table 3) .
toxic effects of chemoradiation, preoperative evaluation, and surgery
Feasibility and acute toxicity of this preoperative chemoradiation regimen have already been reported [29] . Briefly, grade 3/4 toxic effects occurred in 27 patients. All acute early grade ‡3 toxic effects of the treatment are listed in Table 3 . Main toxic effects of the preoperative chemoradiation program were hematologic (14 patients) and digestive (15 patients). In the 40 assessable patients for tumor response, four patients (10%) presented with partial response, 26 (65%) with (Figure 2 ). Ten patients (24%) underwent surgery but not resection despite a satisfying presurgical assessment: at the time of laparotomy, four patients were diagnosed with a vascular involvement, two with liver metastases, one with a peritoneal invasion, two with both vascular involvement and liver metastases, and one with vascular involvement, liver metastases, and peritoneal invasion. Of these 10 patients, six had a palliative surgical digestive bypass. The remaining five patients (12%) did not undergo surgery: one patient presented with liver metastases and two with vascular involvement, one patient experienced a grade 4 hematologic toxicity precluding curative resection, and one patient died just after completion of the presurgical work-up. No statistically significant difference in the surgical resection rate was observed between patients who underwent initial laparoscopy (9 of 14 patients, 64.3%) and those who did not (17 of 27 patients, 63.0%). Surgery complications occurred in 13 of 36 patients (surgical morbidity rate 36%), and one patient died from septic shock at day 3 after pancreaticoduodenectomy (surgical mortality rate 2.8%).
Other postoperative complications consisted of one case of eventually lethal portal thrombosis and fistula, one abdominal hemorrhage requiring surgery, seven infectious episodes, one persistent gastroplegia, one conscious trouble at day 2, one melena episode, and one renutrition difficulty. Late toxic effects were grade 3 lower limbs bilateral neuropathy (one case, in which the patient had received an oxaliplatin-based chemotherapy at the time of recurrence), cachexia (one case), persistent biologic hepatic changes (one case), and grade 4 neuropathy (one case in which the cause, either toxic or paraneoplasic, was not clearly established).
feasibility Twenty-seven patients of the 40 assessable patients (68% of patients; two-sided 95% confidence interval (CI) 50.9% to 81.4%; lower bound of one-sided 95% CI 53.4%] completed the primary end point of the study (i.e. being alive, having received the entire dose of radiation and 75% or more of the chemotherapy dose and without extra-hematological toxicity > grade 3) (Figure 2 ). Only 19 patients (47.5%) reached the primary end point and received surgical resection of the pancreatic tumor. In the eight patients who succeeded to the preoperative treatment but did not undergo resection, surgery was precluded by local and/or metastatic progression, not by chemoradiation toxicity.
measurement of treatment effect
All patients, but one, had invasive adenocarcinoma of the ductular cell type at histopathological examination; the remaining one had acinar cell carcinoma. The main histopathological characteristics of the tumor, including tumor size and location, status of resection margins, pathologic staging, and degree of histological differentiation are given in Table 4 . A pathologic complete response was obtained in one patient (who is still alive without evidence of disease 64 months after surgery). A major pathologic response, defined by Figure 2 ). In the 26 patients who underwent surgical resection of the pancreatic tumor, one (4%) patient presented with an inaugural locoregional recurrence and 15 with metastatic dissemination, mainly located in the liver (eight cases) ( Table 5 ). This local relapse occurred for a patient with microscopically negative resection margins on surgical specimen but without major response to preoperative chemoradiation. Regarding the entire cohort, metastatic recurrence occurred in 31 patients (76%); main metastatic sites were liver (21 cases) and peritoneum (13 cases) ( Table 5) . With a median follow-up of 11 months, median survival time (from the date of registration), 1-year, and 2-year survival rates for the 41 eligible patients were 9.4 months (95% CI 5.7-13.1), 41% (95% CI 26% to 56%), and 20% (95% CI 9% to 34%), respectively ( Figure 3 ). Median survival, 1-year, and 2-year survival rates were 11.7 months, 48%, and 32% for the 26 patients operated with curative intent, 8.5 months, 20%, and 0% for the 10 patients who underwent surgery without resection, and 5.7 months, 40%, and 0% for nonoperated patients (Figure 4 ). From the effective or theoretical (in nonresected patients) time of surgery, median survival, 1-year, and 2-year survival rates were 9.5 months, 42%, and 33% in the 26 patients with resection and 5.6 months, 29%, and 0% in the 15 remaining patients. Median disease-free survival time, 1-year, and 2-year disease-free survival rates for the 23 patients eligible for curative resection were 5 months, 44%, and 22%, respectively. The 2-year survival rate for patients without lymph node involvement was 46.2% compared with 16.7% for pN+ patients (P = 0.097). The median survival times and the 1-year overall survival rates were 9.1 months and 29% (95% CI 9% to 52%) among the 14 patients who underwent laparoscopy at initial staging and 11.9 months and 36% (95% CI 13% to 59%) among the 27 patients who did not. Other histopathological parameters of response to chemoradiation were not associated with overall or disease-free survival.
discussion
The results of this multi-institutional trial, exclusively dedicated to resectable pancreatic cancer, suggest that induction chemoradiation with 5-FU and cisplatin is feasible, with a completion rate of 68% and acceptable hematologic and non-hematologic toxic effects (Table 3 , Figure 2 ). This chemoradiation regimen does not prevent successful surgery, given that our resection rate (63%), involved resection margins (20%), and morbidity rates (36%) favorably compare with previous studies (Table 6 ) [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Moreover, this chemoradiation regimen is associated with histopathological response in 50% (13 patients), including complete response in one and major response in 12.
Several studies have shown the feasibility of neoadjuvant chemoradiation regimens for resectable localized pancreatic adenocarcinoma, with curative resection rates between 45% and 74% and the possibility to perform surgical resection without increased morbidity or mortality [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (Table 6 ). The current results are in accordance with the literature: 67.5% Table 5 . original article Annals of Oncology of the cohort completed the planned schedule, with a 63% resection rate, predominantly with microscopic negative margins (80%). Moreover, toxicity appears to be manageable. Tolerance to preoperative chemoradiation varies within the literature. Hematologic toxicity is higher, occurring in 30% of patients, when combined agents or potent radiosensitizer chemotherapy are used. On the other hand, gastrointestinal tolerance depends mostly on the delivered dose and volume of radiation. Preoperative chemoradiation with 5-FU and cisplatin has also been tested in a phase II trial reported by Moutardier et al. [36] , with a better tolerance than in our study (no reported grade 3/4 toxic effects), but at lower doses of chemotherapy and radiotherapy. Furthermore, their median survival in patients with resection was higher (26.6 months) than in the current study, even though the 2-year survival rates are similar. Similarly, in two recently published experience, gemcitabine-based chemoradiation in the neoadjuvant setting was associated with both hematological and non-hematological toxicity, but no chemoradiation-related death was reported and all patients completed the radiation component of therapy [39, 40] . It is clearly demonstrated that a lower cancer stage and a R0 resection are sine qua non conditions for local control and prolonged survival [2, 9, [15] [16] [17] [18] [19] [20] [21] 43] . In our series, the R0 resection rate was 80.7%, the literature rate of positive resection margins reaching 51% [9, 15, 43, 44] . Regarding the treatment effect of preoperative chemoradiation as measured by histopathological response, comparison between studies is difficult because of the absence of consensus regarding the criteria for identifying nonviable tumor cells and the absence of simple means for quantifying their number and distribution. In the FFCD-SFRO trial, the analysis and the description of the histopathological modifications consecutive to preoperative chemoradiation were planned in the protocol as a secondary end point and was precisely analyzed and described by a single experienced pathologist. We used the criteria previously proposed by Ishikawa et al., which have proven to be simple, easily identifiable, and reproducible [27] : 23 of 26 specimens presented a histopathological response characterized by >50% of SDCC. A pathologic complete response was noted in one patient (4%) and a major pathologic response was noted in 12 (46%). In a study of 54 pancreatic specimens examined after 5-FU-based chemotherapy delivered concurrently with radiotherapy (45 Gy at 1.8 Gy per fraction over 5 weeks plus 5.4 Gy boost to the tumor), White et al. [45] identified 3 of 54 (6%) complete responses with an additional one-third of patient presenting with either small (<10%) or minimal (scattered foci of tumor cells) tumor loads.
Researchers of the MD Anderson used a different grading system for chemoradiation treatment effect described by Evans et al. [30] . In their experience, pathologic responses characterized by >50% nonviable tumor cells were identified in 39% and 20% specimens after standard and rapid fractionation 5-FU-based chemoradiation, respectively, without any complete pathologic response [12, 32, 46] . Concomitant paclitaxel did not provide any advantage over 5-FU-based chemoradiation in terms of resection rate, treatment effect as assessed in the resected specimen, or overall survival [35] . However, histologic assessment of treatment effect after preoperative gemcitabine-based chemoradiation suggests that greater tumor cell killing was generated using gemcitabine as the radiosensitizer compared with FU or paclitaxel, with one complete pathologic response [39] .
An improvement in long-term outcomes for patients achieving complete response after preoperative chemotherapy with or without radiation therapy has been reported for several tumors but not frequently for pancreatic adenocarcinoma [36, 45] . In the MD Anderson's experience, an improved Annals of Oncology original article median survival (33 months) was reported for 53 patients presenting with >51% nonviable tumor cells after preoperative 5-FU-, paclitaxel-, or gemcitabine-based chemoradiation (rapid or standard fractionation) compared with 79 patients with <50% nonviable tumor cells (20 months), although not statistically significant (P = 0.15) [47] . No statistically significant differences in overall survival by treatment effect scores were reported in the two recent MD Anderson gemcitabine-based chemoradiation phase II trials [39, 40] . In the White's series, the lymph node positivity, the presence of large tumor loads, and poor tumor differentiation were independent negative factors [45] . Paradoxically, patients with tumor necrosis had significantly worse survival than patients without tumor necrosis (P < 0.02). In the Fox Chase Cancer Center's series, patients with a mean fibrosis level of ‡80% were more likely to have negative margins and negative lymph nodes, but this parameter was not an independent prognostic factor for overall survival in univariate analysis [48] . Tumor necrosis and degree of fibrosis were not correlated with survival in our series.
Lymph node involvement has been retrospectively reported to be decreased after neoadjuvant chemoradiation [20, 49] . In the Fox Chase Cancer Center's experience reported by Pingpank et al., 74% of patients operated without preoperative chemoradiation had positive lymph nodes compared with 36% for patients operated after preoperative chemoradiation [20] . Similarly, White et al. reported that despite having more locally advanced pancreatic adenocarcinoma on initial staging (21 versus 8%; P < 0.05), patients (82) who received preoperative chemoradiation were less likely to have positive lymph nodes (29 versus 58%, P < 0.01) and had fewer positive lymph nodes (mean: 4 versus 1.9, P < 0.01), compared with 50 patients who underwent pancreaticoduodenectomy without preoperative chemoradiation [49] . The pejorative impact of lymph node involvement after preoperative chemoradiation has been previously reported [39, 45] . Accordingly, in the SFRO-FFCD trial, the 2-year survival rate was 46.2% for patients without lymph node involvement compared with 16.7% for pN+ patients, although not statistically significant (P = 0.097).
Local recurrence rates, reported to be as high as 50%-80% in patients treated with surgery alone, have been retrospectively reported to be decreased after neoadjuvant chemoradiation [20, [50] [51] [52] . In our series, only one local relapse was reported. Moreover, none of the four patients with positive margins recurred locally, suggesting the potentially lower pejorative value of positive surgical margins after preoperative chemoradiation, the presence of cancer cells on the surgical specimen being not necessarily associated with viable disease. In the gemcitabine-based chemoradiation trial reported by Evans et al. [39] , 11% of patients experienced local recurrence as any component of failure, with 3% as isolated local recurrence. However, identification of local recurrence is difficult in this context and because the competing risk of mortality is important, it is possible that patients did not have time to develop local recurrence.
Although comparing survival data across studies is problematic, the median survival for the 26 operated patients in our series (11.7 months) seems to be similar to those observed in studies with adjuvant chemoradiation, between 11 Table 6 . original article Annals of Oncology and 27 months after diagnosis of the pancreatic cancer [2, 3, 21] . However, the median survival of patients operated in the SFRO-FFCD trial appears lower than what was reported in the two recent gemcitabine-based preoperative chemoradiation, where survival duration for patients who underwent resection was superior to 30 months [39] . The median survival of operated patients in our trial is also lower than what was reported in the chemotherapy arms of recent trials investigating the role of adjuvant chemotherapy in patients undergoing resection of pancreatic cancer [4, 5] . In the final analysis of the ESPAC-1, the median survival in the 5-FU/folinic acid chemotherapy arm was 20.1 months, compared with 15.5 months in the no-chemotherapy arm (P = 0.009) [4] . Similarly, in the phase III Charité Onkologie CONKO-001 trial, Oettle et al. randomized 368 patients who underwent curative resection for pancreatic adenocarcinoma to receive either adjuvant chemotherapy with gemcitabine (189 patients) or observation (182 patients). Disease-free survival was 13.4 months (95% CI 11.4-15.3) in the gemcitabine arm and 6.9 months in the observation arm (95% CI 6.1-7.8) (P < 0.001) [5] . Overall median survival was 22.1 months (95% CI 18.4-25.8) for the gemcitabine group and 20.2 months (95% CI 17-23.4) for the surgery alone group, with a 3-year estimated survivals of 34% and 20.5%, respectively (P = 0.06).
Regarding published experiences of preoperative chemoradiation for resectable pancreatic adenocarcinoma, it appears that this approach is feasible, does not prevent successful surgery, allow an optimal patient selection for pancreaticoduodenectomy through exclusion of patients with rapidly progressive metastatic disease, and provides antitumoral effect associated with histopathological response, a high R0 resection rate, and a low local recurrence rate. These results might also suggest, for future trials, that some features such as the absence of lymph node involvement, R0 resection, and the existence of complete histopathological response may be associated with longer survival. Further research is needed to determine the biological difference between responders and nonresponders, evaluate the predictive value of treatment response parameters, and optimize the chemoradiation regimen. Moreover, with the development of novel systemic therapies, locoregional disease control will be necessary for long-term survival. However, despite the potential advantages of preoperative chemoradiation, there is to date no completed phase III study to validate this approach and preoperative chemoradiation for resectable pancreatic adenocarcinoma cannot be recommended as a treatment option, unless part of a clinical trial. 
